Aelis Farma SA Asset Resilience Ratio
Aelis Farma SA asset resilience ratio. Aelis Farma SA (AELIS) has an Asset Resilience Ratio of 69.27% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See AELIS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Aelis Farma SA (2018–2022)
Asset resilience ratio of Aelis Farma SA from 2018 to 2022. This chart shows how Aelis Farma SA's Asset Resilience Ratio has changed over time. Read how much debt does Aelis Farma SA carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Aelis Farma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see AELIS total asset value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €10.79 Million | 69.27% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €10.79 Million | 69.27% |
Asset Resilience Insights
- Very High Liquidity: Aelis Farma SA maintains exceptional liquid asset reserves at 69.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Aelis Farma SA Industry Peers by Asset Resilience Ratio
Compare Aelis Farma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Aelis Farma SA Asset Resilience Ratio by Year (2018–2022)
Aelis Farma SA asset resilience ratio by year from 2018 to 2022. The table below shows the annual Asset Resilience Ratio data for Aelis Farma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 87.79% | €34.43 Million ≈ $40.25 Million |
€39.22 Million ≈ $45.85 Million |
+0.52pp |
| 2021-12-31 | 87.27% | €24.71 Million ≈ $28.89 Million |
€28.31 Million ≈ $33.10 Million |
+7.34pp |
| 2019-12-31 | 79.93% | €5.77 Million ≈ $6.75 Million |
€7.22 Million ≈ $8.44 Million |
-1.31pp |
| 2018-12-31 | 81.24% | €5.12 Million ≈ $5.99 Million |
€6.30 Million ≈ $7.37 Million |
-- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more